1. Primary objectives:
· To determine the maximum tolerated dose (MTD) of CN128 for single oral administration in thalassemia patients aged 16 and above
· To study the pharmacokinetics of CN128 in thalassemia patients aged 16 and above
2. Design:
The study is designed as a randomized, double-blind,